We are live on ! Find out more
MIM

Monashee Investment Management Portfolio holdings

AUM $184M
1-Year Est. Return 197.43%
This Fund
S&P 500
This Quarter Est. Return
+2.5%
1 Year Est. Return
+197.43%
3 Year Est. Return
+447.04%
5 Year Est. Return
+479.31%
10 Year Est. Return
+5,610.42%
AUM
$405M
AUM Growth
-$137M
Cap. Flow
-$131M
Cap. Flow %
-32.46%
Top 10 Hldgs %
79.23%
Holding
289
New
27
Increased
4
Reduced
8
Closed
245

Top Buys

Rank Stock Value
1
VTI icon
Vanguard Total Stock Market ETF
VTI
+$55.6M
2
HYPR icon
Hyperfine
HYPR
+$17.2M
3
ADC icon
Agree Realty
ADC
+$8.67M
4
DCGO icon
DocGo
DCGO
+$6.96M
5
CMPX icon
Compass Therapeutics
CMPX
+$6.63M

Top Sells

Rank Stock Value
1
MRVI icon
Maravai LifeSciences
MRVI
+$9.08M
2
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$7.86M
3
ML
MoneyLion Inc.
ML
+$6.77M
4
RBC icon
RBC Bearings
RBC
+$5.3M
5
BCAB icon
BioAtla
BCAB
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 24.5%
2 Financials 4.73%
3 Real Estate 2.66%
4 Materials 1.45%
5 Consumer Staples 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$646B
$246M 60.73%
1,017,700
+235,400
+30% +$55.6M
HYPR icon
2
Hyperfine
HYPR
$88.4M
$15.7M 3.89%
+2,171,395
New +$17.2M
SLGC
3
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$9.66M 2.39%
830,000
-656,135
-44% -$7.86M
ADC icon
4
Agree Realty
ADC
$9.66B
$8.92M 2.2%
+125,000
New +$8.67M
PRDS
5
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$8.19M 2.02%
+500,000
New +$5.82M
CRBU icon
6
Caribou Biosciences
CRBU
$146M
$7.61M 1.88%
504,377
+55,000
+12% +$1.07M
DCGO icon
7
DocGo
DCGO
$64.2M
$7.01M 1.73%
+750,000
New +$6.96M
CMPX icon
8
Compass Therapeutics
CMPX
$349M
$6.34M 1.57%
+2,000,000
New +$6.63M
VIEW
9
DELISTED
View, Inc. Class A Common Stock
VIEW
$5.87M 1.45%
25,000
– –
FHTX icon
10
Foghorn Therapeutics
FHTX
$278M
$5.49M 1.36%
240,000
-290,581
-55% -$4.18M
NTRA icon
11
Natera
NTRA
$36.4B
$5.14M 1.27%
55,000
+20,000
+57% +$2.08M
OMGA
12
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$5M 1.24%
441,176
– –
FULC icon
13
Fulcrum Therapeutics
FULC
$241M
$4.83M 1.19%
+273,045
New +$5.41M
SOFI icon
14
SoFi Technologies
SOFI
$19.6B
$4.74M 1.17%
+300,000
New +$5.51M
UP icon
15
Wheels Up
UP
$203M
$4.28M 1.06%
4,612
-3,250
-41% -$3.79M
LUCK
16
Lucky Strike Entertainment
LUCK
$959M
$4.06M 1%
+450,000
New +$4.44M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$3.97M 0.98%
300,000
+175,000
+140% +$2.79M
MYPS icon
18
PLAYSTUDIOS Inc
MYPS
$76.2M
$3.95M 0.98%
1,000,000
– –
PCPC
19
DELISTED
Periphas Capital Partnering Corporation
PCPC
$3.56M 0.88%
146,222
– –
XLO icon
20
Xilio Therapeutics
XLO
$59.8M
$3.43M 0.85%
+15,304
New +$3.65M
FOCS
21
DELISTED
Focus Financial Partners Inc. Class A
FOCS
$3.29M 0.81%
+55,000
New +$3.42M
OWL icon
22
Blue Owl Capital
OWL
$6.45B
$3.28M 0.81%
+220,000
New +$3.47M
CLYM
23
Climb Bio
CLYM
$693M
$3.14M 0.78%
300,000
-5,233
-2% -$78K
HAIN icon
24
Hain Celestial
HAIN
$44.6M
$3.09M 0.76%
+72,507
New +$3.09M
HUMA icon
25
Humacyte
HUMA
$168M
$2.9M 0.72%
399,910
-350,090
-47% -$3.46M
1
2 3 4 5

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $184M AUM 33.43% 1-Year Est. Return
SWMG
Sard Wealth Management Group Atlanta, Georgia $184M AUM 11.26% 1-Year Est. Return
AAM
Ameraudi Asset Management New York $184M AUM 15.4% 1-Year Est. Return
IFPL
Investments & Financial Planning LLC Lexington, Kentucky $184M AUM 17.7% 1-Year Est. Return
RFG
RFP Financial Group Atlanta, Georgia $184M AUM 16.06% 1-Year Est. Return
KWM
KMT Wealth Management El Segundo, California $184M AUM 17.2% 1-Year Est. Return
NAM
Nutshell Asset Management Sevenoaks, United Kingdom $184M AUM 2.02% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Monashee Investment Management's Q4 2021 Portfolio in Review

As of Q4 2021, Monashee Investment Management held 289 positions worth $405M, down 25% from $542M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Monashee Investment Management withdrew a net $131M in Q4 2021, closing 245 positions and reducing 8 holdings. Its most notable exit was Maravai LifeSciences, an estimated $9.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 27% a quarter earlier, followed by Financials and Real Estate.

Against the trend, Monashee Investment Management opened a new position in Hyperfine worth $15.7M.

  • Monashee Investment Management's largest Q4 2021 buy was Hyperfine: 2,171,395 shares worth $15.7M.
  • Monashee Investment Management added most to Vanguard Total Stock Market ETF in Q4 2021, an estimated $55.6M increase.
  • Monashee Investment Management's biggest Q4 2021 reduction was SomaLogic, Inc. Class A Common Stock, cutting an estimated $7.86M.
  • Monashee Investment Management fully exited Maravai LifeSciences in Q4 2021, selling an estimated $9.08M.
  • Monashee Investment Management's ten largest holdings make up 79% of its $405M portfolio in Q4 2021.
  • Monashee Investment Management opened 27 new positions and closed 245 in Q4 2021.
  • Monashee Investment Management's portfolio value fell 25% quarter-over-quarter to $405M.

Based on Monashee Investment Management's 13F filing for Q4 2021, filed 7 Feb 2022.